One of the things we have initiated in collaboration with Health Canada is the capacity for a CDR to start our review process in the latter stages of the Health Canada review process, so that for those drugs that offer the potential for treatment of life-threatening or very serious conditions, we could expedite the CDR review process and also bring forward the learnings from the Health Canada review into the CDR. We've completed one such drug review and were able to reach a recommendation within two months of the market approval by Health Canada.
On April 25th, 2007. See this statement in context.